BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10696236)

  • 1. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts.
    Springer ML; Kraft PE; Blau HM
    Somat Cell Mol Genet; 1998 Sep; 24(5):281-9. PubMed ID: 10696236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
    Hofmann A; Blau HM
    Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Okada S; Tokuhisa T; Sakiyama S; Tagawa M
    J Immunol; 2002 Sep; 169(5):2241-5. PubMed ID: 12193688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs.
    Zeytun A; Nagarkatti M; Nagarkatti PS
    Blood; 2000 Mar; 95(6):2111-7. PubMed ID: 10706882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulminant hepatitis by Fas-ligand expression in MRL-lpr/lpr mice grafted with Fas-positive livers and wild-type mice with Fas-mutant livers.
    Li XK; Fujino M; Sugioka A; Morita M; Okuyama T; Guo L; Funeshima N; Kimura H; Enosawa S; Amemiya H; Suzuki S
    Transplantation; 2001 Feb; 71(4):503-8. PubMed ID: 11258428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors.
    Hohlbaum AM; Gregory MS; Ju ST; Marshak-Rothstein A
    J Immunol; 2001 Dec; 167(11):6217-24. PubMed ID: 11714783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas ligand-transfected myoblasts and islet cell transplantation.
    Turvey SE; Gonzalez-Nicolini V; Kingsley CI; Larregina AT; Morris PJ; Castro MG; Lowenstein PR; Wood KJ
    Transplantation; 2000 May; 69(9):1972-6. PubMed ID: 10830245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas ligand on tumor cells mediates inactivation of neutrophils.
    Chen YL; Chen SH; Wang JY; Yang BC
    J Immunol; 2003 Aug; 171(3):1183-91. PubMed ID: 12874204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
    Lau HT; Yu M; Fontana A; Stoeckert CJ
    Science; 1996 Jul; 273(5271):109-12. PubMed ID: 8658177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
    Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
    Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.
    Kim S; Kim KA; Hwang DY; Lee TH; Kayagaki N; Yagita H; Lee MS
    J Immunol; 2000 Mar; 164(6):2931-6. PubMed ID: 10706679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
    Djamali A; Odorico JS
    Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 promotes selection for Fas-mediated apoptotic resistance.
    Maecker HL; Koumenis C; Giaccia AJ
    Cancer Res; 2000 Aug; 60(16):4638-44. PubMed ID: 10969818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.
    Min WP; Gorczynski R; Huang XY; Kushida M; Kim P; Obataki M; Lei J; Suri RM; Cattral MS
    J Immunol; 2000 Jan; 164(1):161-7. PubMed ID: 10605007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.